Lithium and chlorpromazine in psychotic inpatients.
A sample of recently hospitalized psychotic patients was assigned to treatment with lithium or chlorpromazine in a double-blind drug trial. Several diagnostic systems were used to characterize the patients. No relationship was found, regardless of criterion system used, between diagnosis and differences in drug effectiveness; specifically, the presence of "schizophrenic" symptoms did not predict a poor response to lithium. Among patients with physical overactivity, those treated with lithium terminated earlier and had poorer outcome than those treated with chlorpromazine. In patients who were not overactive, the two drugs were equally effective, and chronically psychotic patients had poorer outcomes regardless of drug. Lithium may be an effective treatment for acutely psychotic patients who are not overactive. The use of a lithium trial as a diagnostic tool may be unwarranted.
D000328:Adult; D000341:Affective Disorders, Psychotic / Q000188:drug therapy*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology; D002746:Chlorpromazine / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008094:Lithium / Q000627:therapeutic use*; D016651:Lithium Carbonate; D008297:Male; D011569:Psychiatric Status Rating Scales; D011897:Random Allocation; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D016651:Lithium Carbonate; D008094:Lithium; D002746:Chlorpromazine